Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness

Autor: Xose L. Perez-Fernandez, Virginia Esteve, Pau Cerdà, Antoni Sabate, Sergi Yun, Ferran Bolao, Jose Maria Mora, Maria Quero, Josep Comin-Colet, Elisabet Leiva, E Santacana, A. Riera-Mestre, Albert Ariza-Solé, Guillermo Suarez-Cuartin, Mar Ronda, Merce Gasa, Mariona Llaberia, Ariadna Padullés, Jordi Guardiola, Carlos García-Forero, Francesc Formiga, Salud Santos, F. Mitjavila, Joan Sabater, Adriana Iriarte, Xavier Corbella, Alberto Pasqualetto, Abelardo Montero, Olga Capdevila, Marta Fanlo, Josep M. Cruzado, Josep Llop, Xavier Solanich, Paolo Dallaglio, Manuel Rubio-Rivas, Rafael Moreno-Gonzalez, Monica Gonzalez, David Chivite, Maylin Koo, Ramon Jodar, N Padullés, Xavier Pintó, Antonio Soriano, Arnau Antolí

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
International Journal of Infectious Diseases, Vol 101, Iss, Pp 290-297 (2020)
International Journal of Infectious Diseases

Highlights • Dexamethasone, or alternative steroids, are recommended in severe COVID-19. • The use of tocilizumab in COVID-19, with or without steroids, is still controversial. • Risk for mortality was assessed in 186 COVID-19 patients receivin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6079fd35ce0e0a4471ef552b2a664ef2
https://doi.org/10.1101/2020.08.31.20182428

P264 Impact of the HLA-DQ1*05 alelle on the initial response to infliximab in patients with Inflammatory Bowel Disease

Autor: Francisco Rodríguez-Moranta, Lorena Rodríguez-Alonso, K Serra, A. Ruiz, C Arajol, Jordi Guardiola, N Padullés, Eduardo Sánchez, A Padró, R Blat, Ana Berrozpe, E Santacana, G. Suris Marin

Publikováno v: Journal of Crohn's and Colitis. 15:S301-S302

Background HLA-DQA1*05 Carriage is associated with development of anti-drug antibodies to infliximab in patients With Crohn’s Disease (Sazonovs et al. Gastroenterology 2019). Our group has shown that the presence of this allele is also an independe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7ba0543dd3f9fa25b8e7c5697fbfbe0
https://doi.org/10.1093/ecco-jcc/jjab076.390

Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design

Autor: J Bas, Ariadna Padullés, E Santacana, Katja Serra, Jordi Guardiola, Lorena Rodríguez-Alonso, Francisco Rodríguez-Moranta, Francisco Morandeira, Helena Colom, N Padullés

Publikováno v: Therapeutic drug monitoring. 42(1)

Background and aims Treating patients based on a treat-to-trough approach has been shown to be a cost-effective strategy for inflammatory bowel disease (IBD) patients who have become unresponsive to infliximab (IFX). However, the documented evidence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf6f8f330d1dcd81bfd4c91383092f83
https://pubmed.ncbi.nlm.nih.gov/31283556

6ER-001 Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients

Autor: J Bas, N Padullés, Ariadna Padullés, Lorena Rodríguez-Alonso, Jordi Guardiola, CM Esteban-Sánchez, E Santacana, Helena Colom

Publikováno v: Europe PubMed Central
Eur J Hosp Pharm

BACKGROUND: Serum infliximab (IFX) trough levels (Cmin) have been associated with clinical response. Therapeutic drug monitoring of IFX has been shown to be clinical and cost effective in inflammatory bowel disease (IBD) patients. However, some patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9d1c03b180cd24ecf4fb586f9751f6
https://doi.org/10.1136/ejhpharm-2018-eahpconf.494

Monitorización de agentes biológicos en la artritis reumatoide. (Spanish)

Autor: Gibert, M. Casellas, Zamora, N. Padullés, Zamora, A. Padullés, Juanola-Roura, F. J., Juncosa, E. Santacana, Rego, F. Morandeira, Martínez, N. Carballo, García, F. J. Narváez, Codina, H. Colom

Publikováno v: El Farmacéutico Hospitales; oct2019, Issue 216, p19-42, 24p